Prolyl hydroxylase inhibitors, polydrug use, and the phosphoproteome
Sign Up to like & getrecommendations! Published in 2022 at "Acta Physiologica"
DOI: 10.1111/apha.13898
Abstract: Development of treatment strategies for kidney diseases largely relies on experimental models of ureteral obstruction/tubularinterstitial fibrosis,1,2 acute kidney injury/ ischemia/reperfusion,3,4 cyclosporine toxicity5,6 or diabetic nephropathy.7 However, experimental models only partly replicate the respective human disease.… read more here.
Keywords: prolyl hydroxylase; phd inhibitors; disease; kidney ... See more keywords
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of nephrology"
DOI: 10.1159/000531084
Abstract: Renal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed… read more here.
Keywords: phd inhibitors; chronic kidney; hif phd; sglt2 inhibitors ... See more keywords
Possible Role of PHD Inhibitors as Hypoxia-Mimicking Agents in the Maintenance of Neural Stem Cells’ Self-Renewal Properties
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2018.00169
Abstract: Hypoxia is the most critical factor for maintaining stemness. During embryonic development, neural stem cells (NSCs) reside in hypoxic niches, and different levels of oxygen pressure and time of hypoxia exposure play important roles in… read more here.
Keywords: phd; self renewal; stem cells; role phd ... See more keywords
Effects of Roxadustat on Erythropoietin Production in the Rat Body
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27031119
Abstract: Anemia is a major complication of chronic renal failure. To treat this anemia, prolylhydroxylase domain enzyme (PHD) inhibitors as well as erythropoiesis-stimulating agents (ESAs) have been used. Although PHD inhibitors rapidly stimulate erythropoietin (Epo) production,… read more here.
Keywords: epo; phd inhibitors; production; epo production ... See more keywords